As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Articles
-
-
Transcriptional and free radical responses to LVAD therapy
-
Translating pharmacogenetics from research to routine clinical practice – a survey of the IGNITE Network
-
Machine learning-selected variables associated with CD4 T cell recovery under antiretroviral therapy in very advanced HIV infection
-
Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies
-
Total lymphocyte count in cancer patients with lymphopenia treated with intravenous vitamin C: Results of an observational study
-
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
-
Comparative in vitro cytotoxic, anti-inflammatory and anti-microbiological activities of two indigenous Venda medicinal plants
-
Membrane cholesterol depletion reduces breast tumor cell migration by a mechanism that involves non-canonical Wnt signaling and IL-10 secretion
-
CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan
Aims and scope
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Editor-in-Chief
Francesco Marincola, Refuge Biotechnologies, USA
Journal of Translational Medicine
Translational Medicine Communications is the companion journal to Journal of Translational Medicine.
Advertisement
Annual Journal Metrics
-
Speed
54 days to first decision for reviewed manuscripts only
52 days to first decision for all manuscripts
89 days from submission to acceptance
18 days from acceptance to publication
Usage
27,765 Downloads
8 mentions
Advertisement
